Key Highlights:
- MARIPOSA Phase 3 trial shows RYBREVANT® + LAZCLUZE® significantly improves progression-free survival versus osimertinib.
- Dual EGFR-MET inhibition strategy positions J&J as a potential first-line leader in EGFR-mutated NSCLC.
- FDA and global regulatory filings underway, with potential to reshape lung cancer treatment standards.
Clinical Breakthrough in EGFR-Mutated NSCLC
Johnson & Johnson’s Innovative Medicine segment has announced positive results from the pivotal MARIPOSA Phase 3 trial evaluating RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) for patients with EGFR exon 19 deletion or L858R substitution-mutated advanced non-small cell lung cancer (NSCLC). The combination achieved a statistically significant improvement in progression-free survival (PFS) compared with the current standard-of-care, osimertinib, in the first-line setting.
Targeting EGFR and MET Resistance Pathways
The trial underscores the potential of J&J’s dual-targeted strategy, as RYBREVANT® is a bispecific antibody that binds EGFR and MET while LAZCLUZE® is a third-generation EGFR tyrosine kinase inhibitor. Together, they aim to overcome resistance mechanisms that limit the durability of single-agent TKIs. Investigators reported strong efficacy and safety outcomes, suggesting this combination could extend survival and reduce relapse rates for patients with EGFR-mutated NSCLC.
Regulatory Momentum and Market Implications
Based on MARIPOSA data, Johnson & Johnson has initiated regulatory submissions in the U.S., Europe, and Asia. If approved, this combination could redefine global standards of care in EGFR-mutated NSCLC, a patient population representing nearly 15% of lung cancer cases worldwide. Analysts suggest the treatment could compete directly with Tagrisso, currently the leading EGFR therapy, opening a multi-billion-dollar market opportunity for J&J.
Investor and Industry Confidence
The MARIPOSA results were presented at a major oncology congress, drawing significant attention from oncologists and investors alike. With multiple late-stage trials ongoing, including MARIPOSA-2 and PAPILLON, Johnson & Johnson is solidifying its oncology leadership. The dual approach with antibody + TKI therapy is being closely watched as a potential game-changer in the lung cancer space.
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare leader advancing innovative medicines and technologies to improve patient outcomes. Through its Innovative Medicine and MedTech businesses, J&J delivers therapies in oncology, immunology, neuroscience, and other specialties, transforming standards of care for millions worldwide.
About RYBREVANT®
RYBREVANT® (amivantamab-vmjw) is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. It is approved in the U.S., Europe, and other markets for specific EGFR-mutated NSCLC indications and is under investigation in multiple Phase 1–3 trials, including MARIPOSA, MARIPOSA-2, and PAPILLON.
About LAZCLUZE®
LAZCLUZE® (lazertinib) is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) developed in collaboration with Yuhan Corporation. It is designed to target both the T790M resistance mutation and activating EGFR mutations, with a favorable safety profile. LAZCLUZE® is being studied in several global trials, including MARIPOSA and LASER301.
By